Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-01-25 @ 3:17 AM
Study NCT ID:
NCT00300105
Status:
TERMINATED
Last Update Posted:
2008-03-17
First Post:
2006-03-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C501413', 'term': 'tesaglitazar'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'count': 400}}, 'statusModule': {'whyStopped': 'The development program has been terminated', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2005-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2008-03', 'completionDateStruct': {'date': '2006-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2008-03-14', 'studyFirstSubmitDate': '2006-03-07', 'studyFirstSubmitQcDate': '2006-03-07', 'lastUpdatePostDateStruct': {'date': '2008-03-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2006-03-08', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Adverse events, laboratory variables, physical examination, cardiac evaluation, hypoglycemic events, electrocardiogram, vital signs (blood pressure and pulse), body weight'}], 'secondaryOutcomes': [{'measure': 'Effect of tesaglitazar versus glibenclamide, with or without other oral anti-diabetic drugs on'}, {'measure': 'Time to treatment failure'}, {'measure': 'Changes in glycemic variables: glycosylated hemoglobin A1c and fasting plasma glucose (FPG)'}, {'measure': 'Responder rates and proportion of patients who reach pre-specified target levels for glycosylated hemoglobin A1c and FPG'}, {'measure': 'Markers of insulin resistance by assessment of insulin homeostasis assessment model'}, {'measure': 'Preventing beta-cell function by assessment of changes in the ratios proinsulin/insulin and C-peptide/FPG'}, {'measure': 'Changes in lipid variables (triglyceride, total cholesterol, high-density lipoprotein cholesterol [HDL-C], non-HDL-C, low-density lipoprotein cholesterol, low-density lipoprotein cholesterol/HDL-C, apolipoprotein [Apo] B, ApoA-1, ApoB/ApoA-1'}, {'measure': 'Responder rates and proportion of patients who reach pre-specified target levels for triglyceride and HDL-C'}, {'measure': 'Inflammatory and coagulability markers by assessment of C-reactive protein, fibrinogen, tumor necrosis factor-alpha, and intracellular adhesion molecule-1'}, {'measure': 'Urinary albumin excretion'}, {'measure': 'Central obesity (waist circumference, hip circumference and waist/hip ratio)'}]}, 'conditionsModule': {'keywords': ['Patients diagnosed with type 2 diabetes who have participated in and completed the randomized, double-blind, parallel-group, multi-center study GALLANT 4'], 'conditions': ['Type 2 Diabetes']}, 'descriptionModule': {'briefSummary': 'This is a parallel-group, multi-center, long-term extension study from the GALLANT 4 study to monitor the safety and tolerability of oral tesaglitazar compared with glibenclamide in patients with type 2 diabetes for up to 100 weeks of treatment. The total duration, including treatment and follow-up, is 103 weeks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Provision of a written informed consent\n* Men or women who are \\>=18 years of age\n* Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control\n* Completed the last two visits of randomized treatment period in GALLANT 4\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* New York Heart Association heart failure Class III or IV\n* Treatment with chronic insulin\n* History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)\n* History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)\n* Creatinine levels above twice the normal range\n* Creatine kinase above 3 times the upper limit of normal\n* Previous enrollment in this long-term extension study\n* Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study"}, 'identificationModule': {'nctId': 'NCT00300105', 'briefTitle': 'GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes', 'organization': {'class': 'INDUSTRY', 'fullName': 'AstraZeneca'}, 'officialTitle': 'A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar Therapy in Patients With Type 2 Diabetes', 'orgStudyIdInfo': {'id': 'D6160C00047'}, 'secondaryIdInfos': [{'id': 'EudraCT No 2004-005243-97'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'Tesaglitazar', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'city': 'Hasselt', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 50.93106, 'lon': 5.33781}}, {'city': 'Liège', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'city': 'Sint-Gillis-Waas', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 51.21914, 'lon': 4.12374}}, {'city': 'Steenokkerzeel', 'country': 'Belgium', 'facility': 'Research Site', 'geoPoint': {'lat': 50.91851, 'lon': 4.50989}}, {'city': 'Shatin', 'country': 'Hong Kong', 'facility': 'Research Site', 'geoPoint': {'lat': 22.38333, 'lon': 114.18333}}, {'city': 'Balatonfüred', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.96188, 'lon': 17.87187}}, {'city': 'Budapest', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'city': 'Kaposvár', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.36667, 'lon': 17.8}}, {'city': 'Kecskemét', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 46.90618, 'lon': 19.69128}}, {'city': 'Székesfehérvár', 'country': 'Hungary', 'facility': 'Research Site', 'geoPoint': {'lat': 47.18995, 'lon': 18.41034}}, {'city': 'Gubbio', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 43.34996, 'lon': 12.57309}}, {'city': 'Milan', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'city': 'Perugia', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 43.1122, 'lon': 12.38878}}, {'city': 'Piacenza', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 45.05242, 'lon': 9.69342}}, {'city': 'Reggio Emilia', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 44.69825, 'lon': 10.63125}}, {'city': 'Udine', 'country': 'Italy', 'facility': 'Research Site', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'city': 'Kubang Kerian', 'state': 'Kelantan', 'country': 'Malaysia', 'facility': 'Research Site', 'geoPoint': {'lat': 6.09123, 'lon': 102.27938}}, {'city': 'Kuala Lumpur', 'country': 'Malaysia', 'facility': 'Research Site', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}, {'city': 'Makati City', 'country': 'Philippines', 'facility': 'Research Site', 'geoPoint': {'lat': 14.55027, 'lon': 121.03269}}, {'city': 'Manila', 'country': 'Philippines', 'facility': 'Research Site', 'geoPoint': {'lat': 14.6042, 'lon': 120.9822}}, {'city': 'Pasig', 'country': 'Philippines', 'facility': 'Research Site', 'geoPoint': {'lat': 14.58691, 'lon': 121.0614}}, {'city': 'Krakow', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'city': 'Lublin', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'city': 'Płock', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 52.54682, 'lon': 19.70638}}, {'city': 'Torun', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'city': 'Tychy', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 50.13717, 'lon': 18.96641}}, {'city': 'Warsaw', 'country': 'Poland', 'facility': 'Research Site', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'city': '£ód?', 'country': 'Poland', 'facility': 'Research Site'}, {'city': 'Banská Bystrica', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.73947, 'lon': 19.14932}}, {'city': 'Bratislava', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'city': 'Ilava', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.99769, 'lon': 18.2353}}, {'city': 'Košice', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.71441, 'lon': 21.25802}}, {'city': 'Kysucké Nové Mesto', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.3, 'lon': 18.78333}}, {'city': 'Lučenec', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.33249, 'lon': 19.66708}}, {'city': 'Ľubochňa', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 49.12011, 'lon': 19.16891}}, {'city': 'Nitra', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.30763, 'lon': 18.08453}}, {'city': 'Prešov', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.99923, 'lon': 21.2355}}, {'city': 'Trnava', 'country': 'Slovakia', 'facility': 'Research Site', 'geoPoint': {'lat': 48.37773, 'lon': 17.58603}}, {'city': 'Johannesburg', 'state': 'Gauteng', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'city': 'Cape Town', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'city': 'Durban', 'country': 'South Africa', 'facility': 'Research Site', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'city': 'Bangkok', 'country': 'Thailand', 'facility': 'Research Site', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}], 'overallOfficials': [{'name': 'AstraZeneca Galida Medical Science Director, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AstraZeneca'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}}}}